Biogen (BIIB)
(Delayed Data from NSDQ)
$143.81 USD
-1.06 (-0.73%)
Updated Sep 18, 2025 04:00 PM ET
After-Market: $143.77 -0.04 (-0.03%) 7:58 PM ET
3-Hold of 5 3
A Value F Growth D Momentum C VGM
Fundamental Charts
About Dividend Yield (TTM)
Biogen Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
BIIB 143.81 -1.06(-0.73%)
Will BIIB be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for BIIB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BIIB
Biogen Gets EU Nod for First Postpartum Depression Drug
Will AbbVie's Neuroscience Portfolio Continue to Aid Top-line Growth?
BIIB: What are Zacks experts saying now?
Zacks Private Portfolio Services
IONS Hits 52-Week High on Tryngolza's Success in Lowering Triglyceride
Eli Lilly's New Drugs Beyond Mounjaro and Zepbound Boost Sales
Biogen Secures FDA Nod for Subcutaneous Maintenance Dosing of Leqembi
Other News for BIIB
A Look Into Biogen Inc's Price Over Earnings
Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories!
Biogen (BIIB) to Acquire Alcyone Therapeutics for $85M
December 19th Options Now Available For Biogen (BIIB)
M&A News: Biotech Biogen Buys Alcyone Therapeutics for $85M to Boost Brain Treatments